| T18 |
188-1831 |
Sentence |
denotes |
Geographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal< 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (>50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP > AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay |
